The novel Tiron-based L-BTZ revealed improved therapeutic effects against not only hematological malignancies, but also other carcinomas (HCC in this study) and prolonged plasma circulation time and retention compared to free BTZ (mannitol–BTZ complexes) at the same dose. The gene discussed is CASC3; the disease is carcinoma.